Results 41 to 50 of about 101,624 (260)

EphB1‐Mediated Transient Blood‐Brain Barrier Opening Facilitates a Ferritin‐Based Nanotherapeutic for Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
We constructed a brain‐targeted AFn‐DPZ nanodrug delivery system and identified EphB1 as its receptor on the blood‐brain barrier (BBB). This system facilitates drug transport across the BBB and thereby ameliorates cognitive impairment in Alzheimer's disease.
Shilin Wen   +5 more
wiley   +1 more source

Interaction of early life stress and NAD + /SIRT1 pathway genetic risk promotes depression

open access: yesTranslational Psychiatry
A recent study demonstrated that rodents exposed to early life stress (ELS) showed changes in fat tissue composition and exhibited depression-like phenotype.
Dora Torok   +9 more
doaj   +1 more source

Insights into amoxicillin pharmacokinetics using physiology-based pharmacokinetic modelling

open access: yesAntimicrobial Agents and Chemotherapy
Amoxicillin is the most commonly used antibiotic globally. However, there is a relatively poor understanding of its pharmacokinetics, pharmacodynamics, and clinical pharmacology.
Christopher A. Darlow   +3 more
doaj   +1 more source

In Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke [PDF]

open access: yes, 2023
Alteplase is the only FDA-approved drug for thrombolysis in acute ischemic stroke (AIS). Meanwhile, several thrombolytic drugs are deemed to be promising candidates to substitute alteplase.
Xu, Xiao   +5 more
core   +1 more source

Targeting GALNT7 Disrupts the TAZ O‐GalNAcylation Feedback Loop to Suppress Gallbladder Cancer Progression

open access: yesAdvanced Science, EarlyView.
Aberrant GALNT7‐mediated O‐GalNAcylation stabilizes TAZ to drive gallbladder cancer progression through a feed‐forward transcriptional loop. Structure‐based screening identifies Olaparib as a potent GALNT7 antagonist that disrupts this oncogenic axis, providing an immediate therapeutic strategy for this aggressive malignancy.
Peng Qiu   +11 more
wiley   +1 more source

p38α Mitogen-Activated Protein Kinase—An Emerging Drug Target for the Treatment of Alzheimer’s Disease

open access: yesMolecules
Alzheimer’s disease (AD) is a neurodegenerative disorder, characterized by the formation of amyloid β and tau protein aggregates in the brain, neuroinflammation, impaired cholinergic neurotransmission, and oxidative stress, resulting in the gradual loss ...
Jan Detka   +4 more
doaj   +1 more source

Acute 5-HT2C Receptor Antagonist SB-242084 Treatment Affects EEG Gamma Band Activity Similarly to Chronic Escitalopram

open access: yesFrontiers in Pharmacology, 2020
Serotonin 2C receptors (5-HT2CRs) are implicated in the pathomechanism and treatment of anxiety and depression. Recently, as a new biomarker of depression, alterations in the gamma power of the electroencephalogram (EEG) have been suggested.
Noémi Papp   +11 more
doaj   +1 more source

Enhanced Antibacterial Properties of Lyotropic Liquid Crystalline Nanoparticles via Curvature Modulation

open access: yesAdvanced Science, EarlyView.
Lipid nanostructured particles with increasing negative Gaussian curvature progress from vesicles to P‐cubosomes and D‐cubosomes. This curvature hierarchy enhances interaction with bacterial membranes, promotes membrane remodeling and leakage, and potentiates daptomycin activity against MRSA.
Xiangfeng Lai   +10 more
wiley   +1 more source

Editorial on Special Issue “Pharmacokinetics, Pharmacodynamics, and Drug Interactions”

open access: yes
Pharmacokinetics describes the absorption, distribution, metabolism, and excretion of a drug, while pharmacodynamics focuses on the effects of the drug on the body [...
Zhu Zhou
core   +1 more source

Pharmacodynamics in paramedic practice [PDF]

open access: yes
Pharmacodynamics is the study of how drugs interact with the body to produce their effects, focusing on the mechanisms of drug action and their impact on physiological processes.
Thain, A, Webster, CA
core   +1 more source

Home - About - Disclaimer - Privacy